IQVIA’s Commercial Technology Suite for Global Deployment Selected by Roche
October 16 2018 - 8:00AM
Business Wire
IQVIA (NYSE: IQV) today announced that the pharmaceuticals
division of Roche (F. Hoffmann-La Roche Ltd) has selected IQVIA’s
commercial technology suite for deployment across more than 100
markets. IQVIA’s Technologies suite includes the Orchestrated
Customer Engagement (OCE) Sales/Marketing, Master Data Management
(MDM), ePromo and Organization Manager applications and will be a
key enabler for this industry leader’s efforts to transform
commercial engagement.
The IQVIA Technologies suite will be leveraged to drive more
meaningful customer engagement and interactions, and to better
inform commercial decisions. By seamlessly linking marketing,
sales, medical science liaisons, account management, and other
functions, this integrated portfolio enhances customer experience,
strengthens relationships, and drives performance. The suite is
built on best-in-class platforms, such as Salesforce.com, Mulesoft,
Amazon Web Services, Heroku, and Box.
Under the terms of this multi-year agreement, Roche Pharma will
rollout IQVIA’s OCE Sales, OCE Marketing, Organization Manager,
MDM, and ePromo solutions for approximately 14,000 users across
100+ countries.
This strategic collaboration with a leading innovator in life
sciences utilizes IQVIA’s open technology designs and innovative
biopharma solutions to enable easy deployment across the globe.
IQVIA’s clients can deliver more meaningful and engaging customer
interactions by using global solutions uniquely tailored to the
life sciences industry.
IQVIA delivers innovative solutions that unify different work
groups within life sciences companies, streamline processes,
bolster customer relationships, and drive greater client
understanding to better anticipate and respond to market changes.
Additional information about IQVIA Technologies is available on the
IQVIA website.
About IQVIA
IQVIA (NYSE: IQV) is a leading global provider of advanced
analytics, technology solutions and contract research services to
the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding
scope of human science — to enable companies to reimagine and
develop new approaches to clinical development and
commercialization, speed innovation, and accelerate improvements in
healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers
unique and actionable insights at the intersection of large-scale
analytics, transformative technology, and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100
countries.
IQVIA is a global leader in protecting
individual patient privacy. The company uses a wide variety of
privacy-enhancing technologies and safeguards to protect individual
privacy while generating and analyzing the information that helps
its customers drive human health outcomes forward. IQVIA’s insights
and execution capabilities help biotech, medical device and
pharmaceutical companies, medical researchers, government agencies,
payers, and other healthcare stakeholders tap into a deeper
understanding of diseases, human behaviors, and scientific advances
in an effort to advance their path toward cures. To learn more,
visit www.iqvia.com.
Click here to subscribe to Mobile Alerts for
IQVIA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181016005286/en/
IQVIAMedia RelationsTor Constantino, +1
484-567-6732tor.constantino@iqvia.comorInvestor RelationsAndrew
Markwick, +1 973-257-7144andrew.markwick@iqvia.com
IQVIA (NYSE:IQV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Jul 2023 to Jul 2024